Erythropoietin ameliorates chemotherapy-induced fibrosis of the lungs in a preclinical murine model

International Journal of Cancer

Volumn 122, Issue 12, 2008, Pages 2851-2857

  Sigounas, George ^a   Salleng, Kenneth J ^b   Mehlhop, Paul D ^a   Sigounas, Dimitri G ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Lung fibrosis; Modulators; Protection

Indexed keywords

BLEOMYCIN; ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL STRUCTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; FEMALE; FIBROSING ALVEOLITIS; INFLAMMATION; LUNG FIBROSIS; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; TISSUE SECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLEOMYCIN; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; FEMALE; MICE; MICE, INBRED C57BL; PULMONARY FIBROSIS;

EID: 43049085521     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23426     Document Type: Article

References (52)

1. Perry MC. The chemotherapy source book, 3rd edn. Baltimore: Williams & Wilkins, 2001.
2. Kreisman H, Wolkove N. Pulmonary toxicity of antineoplastic therapy. Semin Oncol 1992;19:508-20.
3. Meadors M, Floyd J, Perry MC. Pulmonary toxicity of chemotherapy. Semin Oncol 2006;33:98-105.
4. Kaminski N. Idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003;29(3 Suppl):S32-S36.
5. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001;120:617-24.
6. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med 2003;228:1-14.
7. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett CL, Langensiepen S, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14.
8. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006;70:246-50.
9. Coleman TR, Westenfelder C, Togel FE, Yang Y, Hu Z, Swenson L, Leuvenink HG, Ploeg RJ, d'Uscio LV, Katusic ZS, Ghezzi P, Zanetti A, et al. Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. PNAS (USA) 2006;103:5965-70.
10. Steiner M, Madigan T, Anagnostou A, Sigounas G. Cloning and characterization of erythropoietin receptor forms of human vascular endothelial cells [abstract]. Blood 1997;90 (Suppl 1):290a.
11. Minamino T, Kitakaze M. New therapeutic application of erythropoietin against ischemic heart diseases. J Pharmacol Sci 2006;101:179-81.
12. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res 2006;12:332-9.
13. Sigounas G, Hooker J, Anagnostou A, Steiner M. S-allylmercaptocysteine inhibits cell proliferation and reduces the viability of erythroleukemia, breast, and prostate cancer cell lines. Nutr Cancer 1997;27:186-91.
14. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988;41:467-70.
15. Sleijfer S, van der Mark TW, Schraffordt Koops H, Mulder NH. Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect. Br J Cancer 1995;71:120-3.
16. Kimura T, Ishii Y, Yoh K, Morishima Y, Iizuka T, Kiwamoto T, Matsuno Y, Homma S, Nomura A, Sakamoto T, Takahashi S, Sekizawa K. Overexpression of the transcription factor GATA-3 enhances the development of pulmonary fibrosis. Am J Pathol 2006;169:96-104.
17. Kinnula VL, Fattman CL, Tan RJ, Oury TD. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005;172:417-22.
18. Hamaguchi Y, Nishizawa Y, Yasui M, Hasegawa M, Kaburagi Y, Komura K, Nagaoka T, Saito E, Shimada Y, Takehara K, Kadono T, Steeber DA, et al. Intercellular adhesion molecule-1 and L-selectin regulate bleomycin-induced lung fibrosis. Am J Pathol 2002;161:1607-18.
19. Matsuse T, Teramoto S, Katayama H, Sudo E, Ekimoto H, Mitsuhashi H, Uejima Y, Fukuchi Y, Ouchi Y. ICAM-1 mediates lung leukocyte recruitment but not pulmonary fibrosis in a murine model of bleomycin-induced lung injury. Eur Respir J 1999;13:71-7.
20. Sato N, Suzuki Y, Nishio K, Suzuki K, Naoki K, Takeshita K, Kudo H, Miyao N, Tsumura H, Serizawa H, Suematsu M, Yamaguchi K. Roles of ICAM-1 for abnormal leukocyte recruitment in the microcirculation of bleomycin-induced fibrotic lung injury. Am J Respir Crit Care Med 2000;161:1681-8.
21. Moseley PL, Hemken C, Hunninghake GW. Augmentation of fibroblast proliferation by bleomycin. J Clin Invest 1986;78:1150-4.
22. Kimura T, Ishii Y, Morishima Y, Shibuya A, Shibuya K, Taniguchi M, Mochizuki M, Hegab AE, Sakamoto T, Nomura A, Sekizawa K. Treatment with alpha-galactosylceramide attenuates the development of bleomycin-induced pulmonary fibrosis. J Immunol 2004;172:5782-9.
23. Huang W, Wang G, Phelps DS, Al-Mondhiry H, Floros J. Combined SP-A-bleomycin effect on cytokines by THP-1 cells: impact of surfactant lipids on this effect. Am J Physiol Lung Cell Mol Physiol 2002;283:L94-L102.
24. Min JK, Kim YM, Kim SW, Kwon MC, Kong YY, Hwang IK, Won MH, Rho J, Kwon YG. TNF-related activation-induced cytokine enhances leukocyte adhesiveness: induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependent NF-κB activation in endothelial cells. J Immunol 2005;175:531-40.
25. Sun Y, Calvert JW, Zhang JH. Neonatal hypoxia/ischemia is associated with decreased inflammatory mediators after erythropoietin administration. Stroke 2005;36:1672-8.
26. Lappin TR, Maxwell AP, Johnston PG. EPO's alter ego: erythropoietin has multiple actions. Stem Cells 2002;20:485-92.
27. Blackwell K, Gascon P, Sigounas G, Jolliffe L. rHuEPO and improved treatment outcomes: potential modes of action. Oncologist 2004;9(Suppl 5):41-7.
28. Sigounas G, Sallah S, Sigounas VY. Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model. Cancer Lett 2004;214:171-9.
29. Kim MO, Kim SH, Shin MJ, Lee DB, Kim TW, Kim KS, Ha JH, Lee S, Park YB, Kim SJ, Ryoo ZY. Human erythropoietin induces lung failure and erythrocytosis in transgenic mice. Mol Cells 2007;23:17-22.
30. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 1998;273:25381-7.
31. Chong ZZ, Kang J, Maiese K. Angiogenesis and plasticity: role of erythropoietin in vascular systems. J Hematother Stem Cell Res 2002;11:863-71.
32. Yoon D, Pastore YD, Divoky V, Liu E, Mlodnicka AE, Rainey K, Ponka P, Semenza GL, Schumacher A, Prchal JT. Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development. J Biol Chem 2006;281:25703-11.
33. Huang LE, Bunn HF. Hypoxia-inducible factor and its biomedical relevance. J Biol Chem 2003;278:19575-8.
34. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood 1999;94:1864-77.
35. Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, Park SK, Yuan J, Hefner C, Chartier C, Lee JS, Jiang S, Niyak NR, et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006;12:793-800.
36. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003;102:1340-6.
37. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, Nico B, Roncali L, Dammacco F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627-36.
38. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990;248:378-81.
39. Yatsiv I, Grigoriadis N, Simeonidou C, Stahel PF, Schmidt OI, Alexandrovitch AG, Tsenter J, Shohami E. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J 2005;19:1701-3.
40. Kilic E, Kilic U, Soliz J, Bassetti CL, Gassmann M, Hermann DM. Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways. FASEB J 2005;19:2026-8.
41. Zhao W, Kitidis C, Fleming MD, Lodish HF, Ghaffari S. Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway. Blood 2006;107:907-15.
42. Silva M, Grillot D, Benito A, Richard C, Nunez G, Fernandez-Luna JL. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 1996;88:1576-82.
43. Martinez-Estrada OM, Rodriguez-Millan E, Gonzalez-De Vicente E, Reina M, Vilaro S, Fabre M. Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability. Eur J Neurosci 2003;18:2538-44.
44. Ghezzi P, Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ 2004;11(Suppl 1):S37-S44.
45. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman TR, Brines M, Ghezzi P. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003;198:971-5.
46. Chong ZZ, Li F, Maiese K. Erythropoietin requires NF-κB and its nuclear translocation to prevent early and late apoptotic neuronal injury during β-amyloid toxicity. Curr Neurovasc Res 2005;2:387-99.
47. Burger RM, Peisach J, Horwitz SB. Activated bleomycin - a transient complex of drug, iron, and oxygen that degrades DNA. J Biol Chem 1981;256:11636-44.
48. Calapai G, Marciano MC, Corica F, Allegra A, Parisi A, Frisina N, Caputi AP, Buemi M. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol 2000;401:349-56.
49. Wang XQ, Vaziri ND. Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 1999;33:894-9.
50. Herman EH, Hasinoff BB, Zhang J, Raley LG, Zhang TM, Fukuda Y, Ferrans VJ. Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity. Toxicology 1995;98:163-75.
51. Eschbach JW. Iron requirements in erythropoietin therapy. Best Practice Clin Haematol 2005;18:347-61.
52. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades. Nature 2001;412:641-7.